Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea

Sang Wook Son; Ji Hyun Lee; Jiyoung Ahn; Sung Eun Chang; Eung Ho Choi; Tae Young Han; Yong Hyun Jang; Hye One Kim; Moon Bum Kim; You Chan Kim; Hyun Chang Ko; Joo Yeon Ko; Sang Eun Lee; Yang Won Lee; Bark Lynn Lew; Chan Ho Na; Chang Ook Park; Chun Wook Park; Kui Young Park; Kun Park; Young Lip Park; Joo Young Roh; Young Joon Seo; Min Kyung Shin; Sujin Lee; Sang Hyun Cho

doi:10.5021/ad.21.239

Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea

Sang Wook Son, Ji Hyun Lee, Jiyoung Ahn, Sung Eun Chang, Eung Ho Choi, Tae Young Han, Yong Hyun Jang, Hye One Kim, Moon Bum Kim, You Chan Kim, Hyun Chang Ko, Joo Yeon Ko, Sang Eun Lee, Yang Won Lee, Bark Lynn Lew, Chan Ho Na, Chang Ook Park, Chun Wook Park, Kui Young Park, Kun ParkYoung Lip Park, Joo Young Roh, Young Joon Seo, Min Kyung Shin, Sujin Lee, Sang Hyun Cho

Dermatology

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Data illustrating the impact of atopic dermatitis (AD) on lives of adults with AD in South Korea are limited. Objective: To assess the AD disease severity and its impact on quality of life (QoL) in patients with AD from South Korea. Methods: Patients with AD utilizing the specialist dermatology services of major hospitals in South Korea were assessed for disease severity using Eczema Area and Severity Index (EASI) score, for QoL using Dermatology Life Quality Index (DLQI) (for QoL), and for comorbidities and treatment experience via retrospective review of 12-month medical records. Clinical and sociodemographic characteristics were also measured. Results: Of the 1,163 patients, 695 (59.8%) were men (mean age [years]±standard deviation: 31.6±12.1). Overall, 52.9% (n=615) patients had moderate-to-severe disease (EASI>7). The QoL of 72.3% (n=840) patients was affected moderately-to-severely (DLQI score: 6~30). Systemic immunosuppressants were used ≥1 over past 12 months in 51.9% (n=603) patients, and the most commonly used were cyclosporines (45.7%, n=531) and systemic corticosteroids (40.5%, n=471). Approximately, 10.8% (n=126) patients consulted or received treatment for AD-related eye problem. Of these, 40% (n=50) patients reported poor, very poor, or completely blind status; approximately, 16.7% patients (n=192) reported having depression or anxiety; and 35.5% (n=410) reported suicidal ideation or suicidal attempt. Conclusion: A large proportion of patients had moderate-to-severe AD, a compromised QoL, and ocular or mental health comorbidities, indicating a high disease burden despite systemic treatment. These findings highlight the importance of a holistic approach for the evaluation and treatment of patients with AD.

Original language	English
Pages (from-to)	419-430
Number of pages	12
Journal	Annals of Dermatology
Volume	34
Issue number	6
DOIs	https://doi.org/10.5021/ad.21.239
Publication status	Published - 2022 Dec

Bibliographical note

Funding Information:
The authors would like to thank the study patients, their family, and caregivers who were involved in this study. Editorial support in the preparation of this publication was provided by Dr. Vijay M Katekhaye of Quest MedPharma Consultants and Ruchi Gupta and Mradul Dubey (both from Tata Consultancy Services India Ltd.) and funded by Sanofi. Editorial support in the preparation of this publication was also provided by Anahita Gouri and Rohan Mitra of Sanofi, India. Data analysis was performed by IQVIA. The authors are individually and collectively responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication.

Funding Information:
The authors would like to thank the study patients, their family, and caregivers who were involved in this study. Editorial support in the preparation of this publication was provided by Dr. Vijay M Katekhaye of Quest MedPharma Consultants and Ruchi Gupta and Mradul Dubey (both from Tata Consultancy Services India Ltd.) and funded by Sanofi. Editorial support in the preparation of this publication was also provided by Anahita Gouri and Rohan Mitra of Sanofi, India. Data analysis was performed by IQVIA. The authors are individually and collectively responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication. This study was funded by Sanofi. The study sponsor took part in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; decision to submit the manuscript for publication.

Publisher Copyright:
Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology.

All Science Journal Classification (ASJC) codes

Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5021/ad.21.239

Cite this

Son, S. W., Lee, J. H., Ahn, J., Chang, S. E., Choi, E. H., Han, T. Y., Jang, Y. H., Kim, H. O., Kim, M. B., Kim, Y. C., Ko, H. C., Ko, J. Y., Lee, S. E., Lee, Y. W., Lew, B. L., Na, C. H., Park, C. O., Park, C. W., Park, K. Y., ... Cho, S. H. (2022). Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea. Annals of Dermatology, 34(6), 419-430. https://doi.org/10.5021/ad.21.239

@article{7ec169eda05d4d53820143e4cc28a2e5,

title = "Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea",

abstract = "Background: Data illustrating the impact of atopic dermatitis (AD) on lives of adults with AD in South Korea are limited. Objective: To assess the AD disease severity and its impact on quality of life (QoL) in patients with AD from South Korea. Methods: Patients with AD utilizing the specialist dermatology services of major hospitals in South Korea were assessed for disease severity using Eczema Area and Severity Index (EASI) score, for QoL using Dermatology Life Quality Index (DLQI) (for QoL), and for comorbidities and treatment experience via retrospective review of 12-month medical records. Clinical and sociodemographic characteristics were also measured. Results: Of the 1,163 patients, 695 (59.8%) were men (mean age [years]±standard deviation: 31.6±12.1). Overall, 52.9% (n=615) patients had moderate-to-severe disease (EASI>7). The QoL of 72.3% (n=840) patients was affected moderately-to-severely (DLQI score: 6~30). Systemic immunosuppressants were used ≥1 over past 12 months in 51.9% (n=603) patients, and the most commonly used were cyclosporines (45.7%, n=531) and systemic corticosteroids (40.5%, n=471). Approximately, 10.8% (n=126) patients consulted or received treatment for AD-related eye problem. Of these, 40% (n=50) patients reported poor, very poor, or completely blind status; approximately, 16.7% patients (n=192) reported having depression or anxiety; and 35.5% (n=410) reported suicidal ideation or suicidal attempt. Conclusion: A large proportion of patients had moderate-to-severe AD, a compromised QoL, and ocular or mental health comorbidities, indicating a high disease burden despite systemic treatment. These findings highlight the importance of a holistic approach for the evaluation and treatment of patients with AD.",

author = "Son, {Sang Wook} and Lee, {Ji Hyun} and Jiyoung Ahn and Chang, {Sung Eun} and Choi, {Eung Ho} and Han, {Tae Young} and Jang, {Yong Hyun} and Kim, {Hye One} and Kim, {Moon Bum} and Kim, {You Chan} and Ko, {Hyun Chang} and Ko, {Joo Yeon} and Lee, {Sang Eun} and Lee, {Yang Won} and Lew, {Bark Lynn} and Na, {Chan Ho} and Park, {Chang Ook} and Park, {Chun Wook} and Park, {Kui Young} and Kun Park and Park, {Young Lip} and Roh, {Joo Young} and Seo, {Young Joon} and Shin, {Min Kyung} and Sujin Lee and Cho, {Sang Hyun}",

note = "Funding Information: The authors would like to thank the study patients, their family, and caregivers who were involved in this study. Editorial support in the preparation of this publication was provided by Dr. Vijay M Katekhaye of Quest MedPharma Consultants and Ruchi Gupta and Mradul Dubey (both from Tata Consultancy Services India Ltd.) and funded by Sanofi. Editorial support in the preparation of this publication was also provided by Anahita Gouri and Rohan Mitra of Sanofi, India. Data analysis was performed by IQVIA. The authors are individually and collectively responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication. Funding Information: The authors would like to thank the study patients, their family, and caregivers who were involved in this study. Editorial support in the preparation of this publication was provided by Dr. Vijay M Katekhaye of Quest MedPharma Consultants and Ruchi Gupta and Mradul Dubey (both from Tata Consultancy Services India Ltd.) and funded by Sanofi. Editorial support in the preparation of this publication was also provided by Anahita Gouri and Rohan Mitra of Sanofi, India. Data analysis was performed by IQVIA. The authors are individually and collectively responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication. This study was funded by Sanofi. The study sponsor took part in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; decision to submit the manuscript for publication. Publisher Copyright: Copyright {\textcopyright} The Korean Dermatological Association and The Korean Society for Investigative Dermatology.",

year = "2022",

month = dec,

doi = "10.5021/ad.21.239",

language = "English",

volume = "34",

pages = "419--430",

journal = "Annals of Dermatology",

issn = "1013-9087",

publisher = "Korean Dermatological Association",

number = "6",

}

Son, SW, Lee, JH, Ahn, J, Chang, SE, Choi, EH, Han, TY, Jang, YH, Kim, HO, Kim, MB, Kim, YC, Ko, HC, Ko, JY, Lee, SE, Lee, YW, Lew, BL, Na, CH, Park, CO, Park, CW, Park, KY, Park, K, Park, YL, Roh, JY, Seo, YJ, Shin, MK, Lee, S & Cho, SH 2022, 'Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea', Annals of Dermatology, vol. 34, no. 6, pp. 419-430. https://doi.org/10.5021/ad.21.239

TY - JOUR

T1 - Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea

AU - Son, Sang Wook

AU - Lee, Ji Hyun

AU - Ahn, Jiyoung

AU - Chang, Sung Eun

AU - Choi, Eung Ho

AU - Han, Tae Young

AU - Jang, Yong Hyun

AU - Kim, Hye One

AU - Kim, Moon Bum

AU - Kim, You Chan

AU - Ko, Hyun Chang

AU - Ko, Joo Yeon

AU - Lee, Sang Eun

AU - Lee, Yang Won

AU - Lew, Bark Lynn

AU - Na, Chan Ho

AU - Park, Chang Ook

AU - Park, Chun Wook

AU - Park, Kui Young

AU - Park, Kun

AU - Park, Young Lip

AU - Roh, Joo Young

AU - Seo, Young Joon

AU - Shin, Min Kyung

AU - Lee, Sujin

AU - Cho, Sang Hyun

N1 - Funding Information: The authors would like to thank the study patients, their family, and caregivers who were involved in this study. Editorial support in the preparation of this publication was provided by Dr. Vijay M Katekhaye of Quest MedPharma Consultants and Ruchi Gupta and Mradul Dubey (both from Tata Consultancy Services India Ltd.) and funded by Sanofi. Editorial support in the preparation of this publication was also provided by Anahita Gouri and Rohan Mitra of Sanofi, India. Data analysis was performed by IQVIA. The authors are individually and collectively responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication. Funding Information: The authors would like to thank the study patients, their family, and caregivers who were involved in this study. Editorial support in the preparation of this publication was provided by Dr. Vijay M Katekhaye of Quest MedPharma Consultants and Ruchi Gupta and Mradul Dubey (both from Tata Consultancy Services India Ltd.) and funded by Sanofi. Editorial support in the preparation of this publication was also provided by Anahita Gouri and Rohan Mitra of Sanofi, India. Data analysis was performed by IQVIA. The authors are individually and collectively responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication. This study was funded by Sanofi. The study sponsor took part in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; decision to submit the manuscript for publication. Publisher Copyright: Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology.

PY - 2022/12

Y1 - 2022/12

N2 - Background: Data illustrating the impact of atopic dermatitis (AD) on lives of adults with AD in South Korea are limited. Objective: To assess the AD disease severity and its impact on quality of life (QoL) in patients with AD from South Korea. Methods: Patients with AD utilizing the specialist dermatology services of major hospitals in South Korea were assessed for disease severity using Eczema Area and Severity Index (EASI) score, for QoL using Dermatology Life Quality Index (DLQI) (for QoL), and for comorbidities and treatment experience via retrospective review of 12-month medical records. Clinical and sociodemographic characteristics were also measured. Results: Of the 1,163 patients, 695 (59.8%) were men (mean age [years]±standard deviation: 31.6±12.1). Overall, 52.9% (n=615) patients had moderate-to-severe disease (EASI>7). The QoL of 72.3% (n=840) patients was affected moderately-to-severely (DLQI score: 6~30). Systemic immunosuppressants were used ≥1 over past 12 months in 51.9% (n=603) patients, and the most commonly used were cyclosporines (45.7%, n=531) and systemic corticosteroids (40.5%, n=471). Approximately, 10.8% (n=126) patients consulted or received treatment for AD-related eye problem. Of these, 40% (n=50) patients reported poor, very poor, or completely blind status; approximately, 16.7% patients (n=192) reported having depression or anxiety; and 35.5% (n=410) reported suicidal ideation or suicidal attempt. Conclusion: A large proportion of patients had moderate-to-severe AD, a compromised QoL, and ocular or mental health comorbidities, indicating a high disease burden despite systemic treatment. These findings highlight the importance of a holistic approach for the evaluation and treatment of patients with AD.

AB - Background: Data illustrating the impact of atopic dermatitis (AD) on lives of adults with AD in South Korea are limited. Objective: To assess the AD disease severity and its impact on quality of life (QoL) in patients with AD from South Korea. Methods: Patients with AD utilizing the specialist dermatology services of major hospitals in South Korea were assessed for disease severity using Eczema Area and Severity Index (EASI) score, for QoL using Dermatology Life Quality Index (DLQI) (for QoL), and for comorbidities and treatment experience via retrospective review of 12-month medical records. Clinical and sociodemographic characteristics were also measured. Results: Of the 1,163 patients, 695 (59.8%) were men (mean age [years]±standard deviation: 31.6±12.1). Overall, 52.9% (n=615) patients had moderate-to-severe disease (EASI>7). The QoL of 72.3% (n=840) patients was affected moderately-to-severely (DLQI score: 6~30). Systemic immunosuppressants were used ≥1 over past 12 months in 51.9% (n=603) patients, and the most commonly used were cyclosporines (45.7%, n=531) and systemic corticosteroids (40.5%, n=471). Approximately, 10.8% (n=126) patients consulted or received treatment for AD-related eye problem. Of these, 40% (n=50) patients reported poor, very poor, or completely blind status; approximately, 16.7% patients (n=192) reported having depression or anxiety; and 35.5% (n=410) reported suicidal ideation or suicidal attempt. Conclusion: A large proportion of patients had moderate-to-severe AD, a compromised QoL, and ocular or mental health comorbidities, indicating a high disease burden despite systemic treatment. These findings highlight the importance of a holistic approach for the evaluation and treatment of patients with AD.

UR - http://www.scopus.com/inward/record.url?scp=85146893126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146893126&partnerID=8YFLogxK

U2 - 10.5021/ad.21.239

DO - 10.5021/ad.21.239

M3 - Article

AN - SCOPUS:85146893126

SN - 1013-9087

VL - 34

SP - 419

EP - 430

JO - Annals of Dermatology

JF - Annals of Dermatology

IS - 6

ER -

Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this